MA26687A1 - 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents
4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenantInfo
- Publication number
- MA26687A1 MA26687A1 MA25764A MA25764A MA26687A1 MA 26687 A1 MA26687 A1 MA 26687A1 MA 25764 A MA25764 A MA 25764A MA 25764 A MA25764 A MA 25764A MA 26687 A1 MA26687 A1 MA 26687A1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydroquinoleines
- carboxyamino
- methyl
- preparation
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10092998P | 1998-09-17 | 1998-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26687A1 true MA26687A1 (fr) | 2004-12-20 |
Family
ID=22282259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA25764A MA26687A1 (fr) | 1998-09-17 | 1999-09-13 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6147090A (fr) |
| EP (1) | EP1114033B1 (fr) |
| JP (1) | JP3655193B2 (fr) |
| AR (1) | AR021482A1 (fr) |
| AT (1) | ATE277906T1 (fr) |
| AU (1) | AU5439899A (fr) |
| BR (1) | BR9913842A (fr) |
| CA (1) | CA2344556A1 (fr) |
| CO (1) | CO5150220A1 (fr) |
| DE (1) | DE69920727T2 (fr) |
| DK (1) | DK1114033T3 (fr) |
| DZ (1) | DZ2889A1 (fr) |
| ES (1) | ES2228086T3 (fr) |
| GT (1) | GT199900149A (fr) |
| HN (1) | HN1999000155A (fr) |
| MA (1) | MA26687A1 (fr) |
| MY (1) | MY121838A (fr) |
| PA (1) | PA8481501A1 (fr) |
| PE (1) | PE20001048A1 (fr) |
| PT (1) | PT1114033E (fr) |
| SI (1) | SI1114033T1 (fr) |
| SV (1) | SV1999000149A (fr) |
| TN (1) | TNSN99172A1 (fr) |
| TW (1) | TWI232859B (fr) |
| WO (1) | WO2000017166A1 (fr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| WO2001076566A1 (fr) | 2000-04-10 | 2001-10-18 | Teva Pharmaceutical Industries Ltd. | Compositions pharmaceutiques stables contenant des acides 7-substitues-3,5-dihydroxyheptanoiques ou acides 7-substitues-3,5-dihydroxyheptenoiques |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1911462A3 (fr) | 2001-01-26 | 2011-11-30 | Schering Corporation | Combinaisons comprenant un inhibiteur d'absorption de stérol |
| RS50406B (sr) | 2001-01-26 | 2009-12-31 | Schering Corporation, | Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije |
| SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| WO2002078625A2 (fr) * | 2001-03-28 | 2002-10-10 | Pharmacia Corporation | Combinaisons therapeutiques pour signes cardiovasculaires et inflammatoires |
| SE0101161D0 (sv) | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
| JP2005500314A (ja) * | 2001-06-21 | 2005-01-06 | ファイザー・プロダクツ・インク | コレステロールエステル転送蛋白インヒビターの自己乳化性製剤 |
| EP1269994A3 (fr) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament |
| PT1404300E (pt) * | 2001-06-22 | 2009-11-09 | Bend Res Inc | Composições farmacêuticas de dispersões de fármacos e polímeros neutros |
| ATE486586T1 (de) | 2001-06-22 | 2010-11-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
| CA2470931A1 (fr) * | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Derives de chalcone et leur utilisation dans le traitement de maladies |
| US7202247B2 (en) | 2001-12-19 | 2007-04-10 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| WO2003063868A1 (fr) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester |
| DE60320940D1 (de) * | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| CN1289467C (zh) | 2002-08-30 | 2006-12-13 | 日本烟草产业株式会社 | 二苄胺化合物及其药物用途 |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| EP1556047A4 (fr) * | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | Antagonistes vis-a-vis du recepteur pgd2 pour le traitement de maladies inflammatoires |
| DE60305724T2 (de) * | 2002-10-21 | 2006-11-09 | Warner-Lambert Co. Llc | Tetrahydrochinolin-derivate als crth2 antagonisten |
| EP1562582A1 (fr) | 2002-11-06 | 2005-08-17 | Schering Corporation | Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination |
| AU2003303239A1 (en) * | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| ATE407670T1 (de) | 2002-12-20 | 2008-09-15 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| US7192944B2 (en) | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| KR20050110017A (ko) * | 2003-03-17 | 2005-11-22 | 니뽄 다바코 산교 가부시키가이샤 | Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법 |
| MXPA05009848A (es) * | 2003-03-17 | 2005-12-06 | Japan Tobacco Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo. |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| CA2526730A1 (fr) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Derives pyrroliques substitues |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| WO2005011635A2 (fr) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles |
| US7317025B2 (en) | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
| WO2005030185A2 (fr) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Procede pour inhiber la production de lipoproteines restantes |
| MXPA06003927A (es) | 2003-10-08 | 2008-02-07 | Lilly Co Eli | Compuestos y metodos para tratar dislipidemia. |
| EP1918000A2 (fr) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires |
| ES2326326T3 (es) | 2004-03-26 | 2009-10-07 | Eli Lilly And Company | Compuestos y procedimientos para tratar la dislipidemia. |
| MY139887A (en) * | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| MX2007003732A (es) * | 2004-09-29 | 2007-04-23 | Schering Corp | Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1. |
| SG163577A1 (en) | 2004-12-03 | 2010-08-30 | Schering Corp | Substituted piperazines as cb1 antagonists |
| US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| EP2548894A1 (fr) | 2005-02-03 | 2013-01-23 | Bend Research, Inc. | Compositions pharmaceutiques à éfficacité améliorée |
| CN101146776A (zh) | 2005-02-24 | 2008-03-19 | 米伦纽姆医药公司 | 治疗炎性疾病的pgd2受体拮抗剂 |
| WO2006098394A1 (fr) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| BRPI0618379A2 (pt) | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| US7897601B2 (en) | 2006-01-18 | 2011-03-01 | Intervet, Inc. | Cannabinoid receptor modulators |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| WO2007090749A2 (fr) | 2006-02-07 | 2007-08-16 | F. Hoffmann-La Roche Ag | Derives de benzamide et d'heteroarene |
| CL2007000667A1 (es) * | 2006-03-14 | 2008-03-14 | Ranbaxi Lab Ltd | Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e |
| WO2007107843A1 (fr) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Procédés de traitement avec des inhibiteurs de la cetp |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| JP2009543773A (ja) * | 2006-07-14 | 2009-12-10 | ランバクシー ラボラトリーズ リミテッド | ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用 |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| AU2008241904B2 (en) | 2007-04-13 | 2012-06-07 | Kowa Company, Ltd. | Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| JP2010531874A (ja) * | 2007-06-28 | 2010-09-30 | インターベット インターナショナル ベー． フェー． | Ｃｂ１アンタゴニストとしての置換ピペラジン |
| WO2009005646A2 (fr) | 2007-06-28 | 2009-01-08 | Schering Corporation | Pipérazines à substitution servant d'antagonistes des récepteurs cb1 |
| EP2217596B8 (fr) | 2007-10-22 | 2013-11-20 | Merck Sharp & Dohme Corp. | Dérivés hétérocycliques bicycliques et leur utilisation en tant que modulateurs de l'activite du gpr 119 |
| EP2297117B1 (fr) | 2008-05-19 | 2012-10-31 | Merck Sharp & Dohme Corp. | Dérivés hétérocycliques bicycliques et leur utilisation en tant que modulateurs de gpr119 |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| EP2379562A1 (fr) | 2008-12-16 | 2011-10-26 | Schering Corporation | Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique |
| WO2010075068A1 (fr) | 2008-12-16 | 2010-07-01 | Schering Corporation | Dérivés de pyridopyrimidine et leurs procédés d'utilisation |
| WO2010075273A1 (fr) | 2008-12-23 | 2010-07-01 | Schering Corporation | Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation |
| US8722882B2 (en) | 2008-12-23 | 2014-05-13 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes |
| JP2012513470A (ja) | 2008-12-23 | 2012-06-14 | シェーリング コーポレイション | 二環式複素環誘導体及びその使用方法 |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| EP2414348B1 (fr) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Dérivés de pipéridine et de pipérazine bicycliques en tant que modulateurs de rcpg pour le traitement de l'obésité, du diabète et d'autres troubles métaboliques |
| WO2011053688A1 (fr) | 2009-10-29 | 2011-05-05 | Schering Corporation | Dérivés de pipéridine bicycliques pontés et leurs procédés d'utilisation |
| US8912206B2 (en) | 2009-11-23 | 2014-12-16 | Merck Sharp & Dohme Corp. | Pyrimidine ether derivatives and methods of use thereof |
| WO2011062885A1 (fr) | 2009-11-23 | 2011-05-26 | Schering Corporation | Dérivés de pyrimidine bicycliques fusionnées et leurs procédés d'utilisation |
| EP2503887B1 (fr) | 2009-11-24 | 2016-01-06 | Merck Sharp & Dohme Corp. | Dérivés de biaryle substitué et leurs procédés d'utilisation |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| MX389591B (es) | 2014-08-29 | 2025-03-20 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA |
| EP3866802B1 (fr) * | 2018-10-17 | 2024-08-21 | Duke University | Inhibiteurs de la quinone réductase 2 destinés à être utilisés en tant qu'agents neuroprotecteurs |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
| US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| JPH0676403B2 (ja) * | 1991-01-18 | 1994-09-28 | エスエス製薬株式会社 | 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤 |
| US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| WO2000038722A1 (fr) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES |
-
1999
- 1999-09-07 US US09/391,273 patent/US6147090A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481501A patent/PA8481501A1/es unknown
- 1999-09-09 HN HN1999000155A patent/HN1999000155A/es unknown
- 1999-09-10 DK DK99940421T patent/DK1114033T3/da active
- 1999-09-10 PE PE1999000923A patent/PE20001048A1/es not_active Application Discontinuation
- 1999-09-10 GT GT199900149A patent/GT199900149A/es unknown
- 1999-09-10 BR BR9913842-5A patent/BR9913842A/pt not_active Application Discontinuation
- 1999-09-10 AU AU54398/99A patent/AU5439899A/en not_active Abandoned
- 1999-09-10 ES ES99940421T patent/ES2228086T3/es not_active Expired - Lifetime
- 1999-09-10 CA CA002344556A patent/CA2344556A1/fr not_active Abandoned
- 1999-09-10 JP JP2000574076A patent/JP3655193B2/ja not_active Expired - Fee Related
- 1999-09-10 TW TW088115690A patent/TWI232859B/zh not_active IP Right Cessation
- 1999-09-10 AR ARP990104556A patent/AR021482A1/es active IP Right Grant
- 1999-09-10 WO PCT/IB1999/001529 patent/WO2000017166A1/fr not_active Ceased
- 1999-09-10 SI SI9930672T patent/SI1114033T1/xx unknown
- 1999-09-10 SV SV1999000149A patent/SV1999000149A/es not_active Application Discontinuation
- 1999-09-10 EP EP99940421A patent/EP1114033B1/fr not_active Expired - Lifetime
- 1999-09-10 DE DE69920727T patent/DE69920727T2/de not_active Expired - Fee Related
- 1999-09-10 PT PT99940421T patent/PT1114033E/pt unknown
- 1999-09-10 AT AT99940421T patent/ATE277906T1/de not_active IP Right Cessation
- 1999-09-10 CO CO99057639A patent/CO5150220A1/es unknown
- 1999-09-10 MY MYPI99003922A patent/MY121838A/en unknown
- 1999-09-13 TN TNTNSN99172A patent/TNSN99172A1/fr unknown
- 1999-09-13 MA MA25764A patent/MA26687A1/fr unknown
- 1999-09-17 DZ DZ990189A patent/DZ2889A1/fr active
-
2000
- 2000-09-27 US US09/671,400 patent/US6395751B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SV1999000149A (es) | 2000-07-06 |
| WO2000017166A1 (fr) | 2000-03-30 |
| EP1114033B1 (fr) | 2004-09-29 |
| DK1114033T3 (da) | 2004-12-20 |
| AU5439899A (en) | 2000-04-10 |
| DE69920727D1 (en) | 2004-11-04 |
| PA8481501A1 (es) | 2001-12-14 |
| BR9913842A (pt) | 2001-06-12 |
| PT1114033E (pt) | 2004-12-31 |
| GT199900149A (es) | 2001-03-03 |
| DE69920727T2 (de) | 2006-03-09 |
| TWI232859B (en) | 2005-05-21 |
| ES2228086T3 (es) | 2005-04-01 |
| TNSN99172A1 (fr) | 2005-11-10 |
| US6147090A (en) | 2000-11-14 |
| JP2002526477A (ja) | 2002-08-20 |
| US6395751B1 (en) | 2002-05-28 |
| JP3655193B2 (ja) | 2005-06-02 |
| AR021482A1 (es) | 2002-07-24 |
| DZ2889A1 (fr) | 2003-12-15 |
| EP1114033A1 (fr) | 2001-07-11 |
| ATE277906T1 (de) | 2004-10-15 |
| PE20001048A1 (es) | 2000-10-17 |
| CA2344556A1 (fr) | 2000-03-30 |
| MY121838A (en) | 2006-02-28 |
| HN1999000155A (es) | 2000-01-12 |
| SI1114033T1 (en) | 2005-02-28 |
| CO5150220A1 (es) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26687A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26686A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26622A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26654A1 (fr) | Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| MA26471A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26468A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26638A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant | |
| MA26424A1 (fr) | Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2740136B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant | |
| MA26479A1 (fr) | Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26438A1 (fr) | Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26571A1 (fr) | Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation | |
| MA26439A1 (fr) | Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26680A1 (fr) | Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26614A1 (fr) | Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26653A1 (fr) | Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26499A1 (fr) | Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant . | |
| FR2751334B1 (fr) | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| MA26465A1 (fr) | Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant |